(Q34574834)

3 August 2017

1 reference

title

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies (English)

1 reference

3 August 2017

1 reference

Mitsuo Satoh

1

1 reference

3 August 2017

Shigeru Iida

series ordinal

2

1 reference

3 August 2017

Kenya Shitara

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Biological Therapy

3 August 2017

published in

1 reference

3 August 2017

volume

6

1 reference

3 August 2017

issue

11

1 reference

3 August 2017

page(s)

1161-1173

1 reference

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Replacing the complementarity-determining regions in a human antibody with those from a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Reshaping human antibodies: grafting an antilysozyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Structure and function of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Upping the ante on antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

B cell targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Anti-angiogenic strategies in gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

How do U.S. medical oncologists learn and apply new clinical trials information from press releases in nonmedical media? A case study based on ECOG 4599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Lung Cancer Highlights from ASCO 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Engineered antibody Fc variants with enhanced effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Glycosylation of recombinant antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

History of antibody therapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Rituximab (Rituxan/MabThera): the first decade (1993-2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Clinical Experience with Trastuzumab (Herceptin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

The ErbB receptor family: a therapeutic target for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Interaction sites on human IgG-Fc for FcgammaR: current models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Crystallographic structure studies of an IgG molecule and an Fc fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Biological significance of carbohydrate chains on monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Effect of glycosylation on antibody function: implications for genetic engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Molecular cloning of mouse alpha-1,6-fucosyltransferase and expression of its mRNA in the developing cerebrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Ancestral exonic organization of FUT8, the gene encoding the alpha6-fucosyltransferase, reveals successive peptide domains which suggest a particular three-dimensional core structure for the alpha6-fucosyltransferase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

Production of functional chimaeric mouse/human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1161

10.1517/14712598.6.11.1161

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference